收藏切换
Clinical research progress of mesenchymal-epithelial transition factor inhibitor tepotinib
收藏切换
Yan REN1, 2, Lu WANG2, Ziwen DING2, Junlong WANG3, Jingyi FENG3, Yunliang QIU4, *, Na NI2, 3, *
World Clinical Drug | 2022, 43(7) : 839 - 843
Less
收藏切换
World Clinical Drug | 2022, 43(7): 839-843
• Topic •
Clinical research progress of mesenchymal-epithelial transition factor inhibitor tepotinib
Full
Yan REN1, 2, Lu WANG2, Ziwen DING2, Junlong WANG3, Jingyi FENG3, Yunliang QIU4, *, Na NI2, 3, *
Affiliations
  • 1.College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
  • 2.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 3.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China
  • 4.Shanghai Innostar Biotechnology Co., Ltd., Shanghai 201203, China
Published: 2022-07-10 doi: 10.13683/j.wph.2022.07.005
Outline
收藏切换

Mesenchymal-epithelial transition factor (MET) is an important tumor driver gene in non-small cell lung cancer (NSCLC). In recent years, targeted therapy for MET signaling pathway has become a new target for lung cancer treatment. As the world's first oral, highly selective and potent MET inhibitor, tepotinib has been approved by Japan and the United States FDA for the treatment of advanced or recurrent NSCLC patients with unresectable and MET exon 14 skipping mutations. At the same time, it has shown good safety and efficacy in clinical studies. This article mainly reviewed the current clinical studies of tepotinib in NSCLC, liver cancer, NSCLC with brain metastasis and so on.

mesenchymal-epithelial transition factor inhibitor  /  tepotinib  /  clinical research  /  antineoplastic
任燕, 汪璐, 丁子文, 王俊龙, 冯静怡, 邱云良, 倪娜. 间质上皮细胞转化因子抑制剂特泊替尼的临床研究进展. 世界临床药物, 2022 , 43 (7) : 839 -843 . DOI: 10.13683/j.wph.2022.07.005
Yan REN, Lu WANG, Ziwen DING, Junlong WANG, Jingyi FENG, Yunliang QIU, Na NI. Clinical research progress of mesenchymal-epithelial transition factor inhibitor tepotinib[J]. World Clinical Drug, 2022 , 43 (7) : 839 -843 . DOI: 10.13683/j.wph.2022.07.005
Year 2022 volume 43 Issue 7
9
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.07.005
  • Receive Date:2021-12-01
  • Online Date:2026-11-19
  • Published:2022-07-10
Article Data
Affiliations
History
  • Received:2021-12-01
Affiliations
    1.College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
    2.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
    3.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China
    4.Shanghai Innostar Biotechnology Co., Ltd., Shanghai 201203, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.07.005
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT